| 4 | STATE STREET CORP | 4.8M | $38.2M | +3.5% | 2.793% | 0.00% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 4.7M | $37.4M | +10.0% | 2.733% | 0.00% |
| 6 | Nuveen, LLC | 4.4M | $34.7M | +50.3% | 2.540% | 0.01% |
| 7 | Rosalind Advisors, Inc. | 2.9M | $23.0M | -10.0% | 1.685% | 8.56% |
| 8 | Qube Research & Technologies Ltd | 2.9M | $22.9M | -29.7% | 1.676% | 0.02% |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.6M | $20.8M | -1.5% | 1.521% | 0.00% |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 2.4M | $18.7M | +8.9% | 1.370% | 0.00% |
| 11 | MORGAN STANLEY | 2.3M | $18.5M | -9.2% | 1.354% | 0.00% |
| 12 | Legal & General Group Plc | 2.0M | $15.9M | +5.5% | 1.166% | 0.00% |
| 13 | ARMISTICE CAPITAL, LLC | 2.0M | $15.5M | +2.6% | 1.134% | 0.19% |
| 14 | TWO SIGMA INVESTMENTS, LP | 1.9M | $14.9M | -2.0% | 1.092% | 0.01% |
| 15 | Parkman Healthcare Partners LLC | 1.8M | $14.3M | +5.0% | 1.047% | 1.47% |
| 16 | ALGERT GLOBAL LLC | 1.7M | $13.8M | +50.6% | 1.010% | 0.16% |
| 17 | NORTHERN TRUST CORP | 1.6M | $12.7M | +10.6% | 0.925% | 0.00% |
| 18 | GOLDMAN SACHS GROUP INC | 1.6M | $12.6M | -1.2% | 0.923% | 0.00% |
| 19 | AQR CAPITAL MANAGEMENT LLC | 1.5M | $12.2M | +10.5% | 0.893% | 0.00% |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.5M | $11.8M | +9.8% | 0.864% | 0.00% |
| 21 | FEDERATED HERMES, INC. | 1.4M | $11.4M | +67.4% | 0.831% | 0.02% |
| 22 | BANK OF AMERICA CORP /DE/ | 1.4M | $11.1M | +59.8% | 0.809% | 0.00% |
| 23 | UBS Group AG | 1.3M | $10.3M | -21.0% | 0.754% | 0.00% |
| 24 | Ishara Investments LP | 1.2M | $9.7M | +20.0% | 0.713% | 7.16% |
| 25 | VANGUARD FIDUCIARY TRUST CO | 1.2M | $9.7M | +8.0% | 0.709% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in XERS — a direct measure of their conviction.
| 54.45% |
| +11.02 pp |
| $456M |
| +113% |
| Q4 2024 | 160 | +13% | 43.43% | +0.33 pp | $214M | +22% |
| Q3 2024 | 142 | — | 43.10% | — | $175M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
29 institutions opened new positions in XERS during Q2 2026, while 25 fully exited. 175 added to existing positions and 26 trimmed.
XERS institutional ownership rose by 1.45 percentage points quarter-over-quarter, with a net change of +6 holders.
The top 10 institutions account for 50.2% of all reported 13F value in XERS, and the top 25 account for 72.8%.
Across the largest Rare Disease Biotech peers, institutional ownership levels are: IRLA (23.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.